Navigation Links
NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Date:1/3/2008

SOPHIA ANTIPOLIS, France, Jan. 3 /PRNewswire/ -- NicOx S.A. (Euronext Paris: COX) today announced that Pfizer Inc (NYSE: PFE) has initiated a dose-ranging phase 2 clinical study for PF-03187207 in Japan. PF-03187207 is a new experimental medicine for the treatment of glaucoma, which is currently in an ongoing phase 2 proof-of-concept study in the United States (see press releases of March 28 and 29, 2007). Glaucoma and ocular hypertension are a group of severe eye diseases that can lead to blindness and this new Japanese study will compare the safety and efficacy of PF-03187207 to Xalatan(R) (latanoprost) in Japanese patients with these conditions. Xalatan(R) is a proprietary Pfizer product and the leader in worldwide glaucoma sales, with approximately $1.5 billion of franchise sales in 2006.

PF-03187207 is the lead development compound generated under the August 2004 collaboration agreement between Pfizer and NicOx, which focuses on the research and development of nitric oxide-donating prostaglandin F2-alpha analogs for the treatment of glaucoma (see NOTE).

Maarten Beekman, Vice President of Clinical Development at NicOx, said: "We believe the initiation of this separate Japanese study for PF-03187207 highlights Pfizer's determination to rapidly advance this clinical program towards coordinated regulatory filing in the world's major pharmaceutical markets. Preclinical results have suggested that NicOx' technology has the potential to deliver improved treatments for glaucoma and we look forward to the results of the ongoing proof-of-concept phase 2 study for PF-03187207 in the United States."

Design and rationale for the study

The first clinical study for PF-03187207, initiated in March 2007 in the United States
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
(Date:1/14/2014)... New York , January 14, 2014 ... Closed System Transfer Devices (CSTD) for hazardous drugs, today announced ... for the fourth straight year.   ... for pharmacy technicians, pharmacists, nurses and other medical ...
(Date:1/14/2014)... Spark Therapeutics , a late-stage gene therapy company, has ... a Phase 3 study for inherited retinal dystrophies caused by mutations ... Marrazzo , is presenting this and other corporate updates today, at ... Francisco . Marrazzo said Spark was able to achieve its ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... Accuray Incorporated (Nasdaq: ARAY ), the premier ... investor meeting on Monday, October 3, at the annual meeting ... Beach, Florida. The meeting is open to institutional investors and ... meeting, beginning at 7:00 a.m. E.D.T. on Monday, October 3 ...
... 25, 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... on hospital acute care and gastroenterology markets, today announced ... Stifel Nicolaus 2011 Healthcare Conference at the Four Seasons ... a.m. Eastern Time. The presentation will be ...
Cached Medicine Technology:Accuray Incorporated to Host Investor Meeting at ASTRO 2011 2
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... the potential to ward off depression among retirees, particularly ... online in The Journals of Gerontology, Series ... the article " Internet Use and Depression Among Retired ... ," the authors report that Internet use reduced the ... their study sample. , Late-life depression affects between ...
(Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...
(Date:4/17/2014)... Giving patients adrenaline after they suffer a cardiac arrest ... of surviving long-term, according to new research conducted at ... who have a cardiac arrest get adrenaline, which has ... decades," said Dr. Steve Lin, an emergency physician and ... in medical treatment, long-term survival rates of patients who ...
Breaking Medicine News(10 mins):Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... 12-to-1 Return on Investment, MINNEAPOLIS, March 21 ... Therapy Management (MTM) as a benefit option,to employer ... published in the,Journal of the American Pharmacists Association ... MTM services through improved health,outcomes and lower total ...
... A CI head once noted that,"Competitive Intelligence is like ... you realize you need it is when it is ... companies need competitive,intelligence to effectively deal with a turbulent ... that people begin to realize how,critical competitive intelligence is ...
... in Stopping Deadly High-Pressure Bleeding, BETHESDA, Md., ... Research (ISR), the world,s premier ballistic injury research,facility, ... that TraumaCure,s,ground- breaking product, WoundStat(TM), is the most ... the number one cause of,death for soldiers in ...
... Inc. (OTC,Bulletin Board: RXEI), a developer, manufacturer, ... today announced the signing of a,multi-source contract ... of RxElite,s,anesthetic gas products, Sevoflurane and Isoflurane. ... all classes of trade and the,company,s anesthetic ...
... biomarkers for diabetes, heart disease than in males , , ... damage to their cardiovascular health from poor sleep than ... believe they,ve determined why. , They found that ... higher levels of biomarkers associated with increased risk of ...
... in Three Categories: Sustainable Technology, Life Sciences, ... ... winners of the 2008 McGinnis,Venture Competition, which awarded more than $140,000 ... of Business at,Carnegie Mellon University, Yale University and the University of ...
Cached Medicine News:Health News:ClearScript Offers Innovative Medication Therapy Management Program to Employee Health Plans 2Health News:New Research Uncovers How to Build and Maintain an Effective Competitive Intelligence Group 2Health News:U.S. Army Study Reports WoundStat(TM) is Most Effective 2Health News:U.S. Army Study Reports WoundStat(TM) is Most Effective 3Health News:RxElite Awarded Anesthetic Gases Multi-Source Contract by Premier Inc., a Purchasing Network for More than 1,500 U.S. Hospitals and 49,000 Other Healthcare Sites 2Health News:RxElite Awarded Anesthetic Gases Multi-Source Contract by Premier Inc., a Purchasing Network for More than 1,500 U.S. Hospitals and 49,000 Other Healthcare Sites 3Health News:Lack of Sleep Hurts Women's Hearts Most 2Health News:Teams From Carnegie Mellon, Yale, Manitoba Win Tepper School's 2008 McGinnis Venture Competition 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: